Androgen deprivation therapy for prostate cancer: Implications for cardiometabolic clinical care

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2012-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3275/8284PMID 22391014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2013cited by this paper
• Clinical exercise interventions in prostate cancer patients—a systematic review of randomized controlled trials

  2012cited by this paper
• Clinical exercise interventions in prostate cancer

  2012cited by this paper
• A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

  2012cited by this paper
• Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study.

  2011cited by this paper
• Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Cancer statistics, 2011

  2011cited by this paper
• Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

  2011cited by this paper
• What do prostate cancer patients die of?

  2011cited by this paper
• Androgen Deprivation Therapy and the Risk of Coronary Heart Disease and Heart Failure in Patients with Prostate Cancer

  2011cited by this paper
• Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

  2010cited by this paper
• Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

  2010cited by this paper
• Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

  2010cited by this paper
• An update on androgen deprivation therapy for prostate cancer.

  2010cited by this paper
• Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes

  2010influential reference
• The management of metastatic prostate cancer

  2009cited by this paper
• Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

  2009cited by this paper
• Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

  2009cited by this paper
• Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues

  2009cited by this paper
• Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

  2009cited by this paper
• Metabolic Changes During Gonadotropin-releasing Hormone Agonist Therapy For Prostate Cancer: Differences From the Classic Metabolic Syndrome

  2009cited by this paper
• Ten-Year Follow-up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

  2009cited by this paper
• Duration of androgen suppression in the treatment of prostate cancer.

  2009cited by this paper
• Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As

  2009cited by this paper
• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2009cited by this paper
• Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

  2008cited by this paper
• Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

  2008cited by this paper
• Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

  2008cited by this paper
• Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.

  2008cited by this paper
• Metabolic and cardiovascular effects of androgen deprivation therapy

  2008cited by this paper
• Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer

  2008cited by this paper
• Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

  2008cited by this paper
• Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.

  2008cited by this paper
• Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

  2008cited by this paper
• Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

  2008cited by this paper
• Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

  2007cited by this paper
• Androgen deprivation therapy for prostate cancer: new concepts and concerns

  2007cited by this paper
• Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer

  2007cited by this paper
• Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

  2007cited by this paper
• Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

  2007cited by this paper
• Rising PSA in nonmetastatic prostate cancer.

  2007cited by this paper
• Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

  2006cited by this paper
• Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapy

  2006cited by this paper
• Insulin sensitivity during combined androgen blockade for prostate cancer.

  2006cited by this paper
• Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

  2006cited by this paper
• Metabolic syndrome.

  2006cited by this paper
• Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

  2006cited by this paper
• Endocrine complications of androgen-deprivation therapy in men with prostate cancer.

  2006cited by this paper
• Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

  2005cited by this paper
• Adverse events associated with hormonal therapy for prostate cancer.

  2005cited by this paper
• The influence of androgen deprivation therapy on metabolism in patients with prostate cancer.

  2005cited by this paper
• Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma

  2005cited by this paper
• Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma

  2005cited by this paper
• Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

  2005cited by this paper
• Endocrine treatment of prostate cancer.

  2004cited by this paper
• Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

  2004cited by this paper
• The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action.

  2003cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Changes in body composition during androgen deprivation therapy for prostate cancer.

  2002cited by this paper
• The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

  2002cited by this paper
• Long‐term effects of androgen deprivation therapy in prostate cancer patients

  2002cited by this paper
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

  2002cited by this paper
• Critical evaluation of hormonal therapy for carcinoma of the prostate.

  2002cited by this paper
• Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

  2001cited by this paper
• The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

  2001cited by this paper
• Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

  2001cited by this paper
• Transperineal brachytherapy in patients with large prostate glands

  2000cited by this paper
• Fatigue in patients with prostate cancer receiving hormone therapy.

  2000cited by this paper
• Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.

  2000cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  2000cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Fatigue in patients with prostate cancer receiving hormone therapy

  1999cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  1999cited by this paper
• Cause of death in men diagnosed with prostate carcinoma

  1998cited by this paper
• Management of metastatic prostate cancer

  1998cited by this paper
• [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin].

  1998cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper
• Noncancer deaths in white adult cancer patients.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• Nonhormonal mechanism of sexual inadequacy in patients with varicocele.

  1985cited by this paper
• Management of metastatic prostatic cancer.

  1985cited by this paper
• STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND

  1941cited by this paper

• The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review

  2020cites this paper
• Androgen Deprivation Therapy and Cardiovascular Risk

  2017cites this paper
• Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective

  2016cites this paper
• Kardiovaskuläres Risiko unter Androgendeprivationstherapie zur Behandlung des hormonabhängigen Prostatakarzinoms

  2016influential citation
• [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

  2016cites this paper
• Features of endometrial cancer in patients with ‘metabolically healthy’ versus ‘standard’ obesity: the decreasing frequency of metabolically healthy obesity

  2015cites this paper
• Choosing a prostate cancer drug.

  2014cites this paper
• Complications de l’hormonothérapie anti-androgénique du cancer de la prostate

  2014cites this paper
• Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.

  2014cites this paper
• [Not Available].

  2014cites this paper
• Androgen deprivation for prostate cancer: when and how, the good and the bad.

  2013cites this paper
• MODULATION OF SEXUAL AND SLEEP FUNCTIONS BY ESTROGEN IN CASTRATED MALE RATS AS A MODEL FOR PROSTATE CANCER PATIENTS ON ANDROGEN DEPRIVATION THERAPY

  2013influential citation
• The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

  2013cites this paper
• Differential effects of estrogen receptor ligands on regulation of dihydrotestosterone-induced cell proliferation in endothelial and prostate cancer cells

  2012cites this paper
• Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains

  2005cites this paper